Allergy Therapeutics PLC Stock
€0.12
Your prediction
Allergy Therapeutics PLC Stock
Pros and Cons of Allergy Therapeutics PLC in the next few years
Pros
Cons
Performance of Allergy Therapeutics PLC vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allergy Therapeutics PLC | 0.000% | 4.464% | 3.540% | 73.333% | 0.000% | 146.316% | -48.684% |
| Beximco Pharmaceuticals Ltd. GDR | 0.000% | 0.000% | 4.444% | 5.381% | 4.911% | 4.444% | -51.546% |
| Eledon Pharmaceuticals Inc. | -9.090% | -10.714% | 15.385% | 4.167% | 134.375% | 42.857% | -64.706% |
| SELLAS Life Sciences Group Inc | -3.750% | -14.382% | -12.313% | 224.532% | 34.392% | 209.253% | -43.847% |
News
Former Dividend Aristocrat AT&T Posts Strong Earnings, Tries to Win Back Investors
It’s not often that a 141-year-old company has the opportunity to generate excitement. But after AT&T (NYSE: T) reported Q1 2026 earnings on April 22, that is exactly how the market has been
Stock Market Today, April 22: AT&T Edges Upwards on Mixed Earnings
AT&T (NYSE:T), a telecommunications and technology services provider, closed Wednesday at $25.98, up 0.39%. The stock has fallen 8.23% in the past month, and today’s Q1 results went some way to
The Market Is Selling Everything, but These 5 Stocks Aren't Breaking Down
The Iran conflict has given investors a reason to sell just about everything. The Dow is in correction territory. Oil prices have surged. Entire sectors are trading as if a recession is already


